BOSTON & SYDNEY, Australia--(BUSINESS WIRE)--Aug. 1, 2006--Scientists at Proteome Systems (ASX:PXL), the globally recognized diagnostics development and drug discovery company, have made an important breakthrough in their quest for developing a new diagnostic test for prostate cancer. They have identified a prostate-specific glycoprotein that is linked to Human Carcinoma Antigen (HCA). A diagnostic test that detects both the glycoprotein and the HCA modification will be highly specific for diagnosing prostate cancer using semen samples.
